Recs

0

The Demise of a Multibillion-Dollar Drug Class?

By | More Articles
March 18, 2013 | Comments (0)

In the following video, Motley Fool health-care analyst David Williamson highlights a potential new threat to an entire class of multibillion-dollar drugs. The drug group, which treats type 2 diabetes, could be linked to pancreatitis, a very serious inflammation of the pancreas that can lead to pancreatic cancer. David tells investors how several companies, such as Merck (NYSE: MRK  ) , Bristol-Myers Squibb (NYSE: BMY  ) and AstraZeneca (NYSE: AZN  ) could be affected if the link is confirmed, and how serious the damage could be financially.

Can Merck beat the patent cliff?
This titan of the pharmaceutical industry stumbled into 2013 and continues to battle patent expirations and pipeline problems. Is Merck still a solid dividend play, or should investors be looking elsewhere? In a new premium research report on Merck, the Fool tackles all of the company's moving parts, its major market opportunities, and reasons to both buy and sell. To find out more click here to claim your copy today.


Jeff Fischer and team have demystified options. And they can rack up income like $1,030... $2,626... and $3,228 on a schedule you can set your watch by!
That's why we're glad to announce every single one of their closely guarded strategies is available to YOU during May and June – 100% FREE, no strings attached! Just enter your email address in the box below...

David Williamson and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

DocumentId: 2319293, ~/Articles/ArticleHandler.aspx, 5/20/2013 10:46:07 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 15,350.93 -3.47 -0.02%
S&P 500 1,668.22 0.75 0.04%
NASD 3,502.52 3.55 0.10%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/20/2013 10:26 AM
MRK $45.47 Down -0.52 -1.13%
Merck & Co., Inc. CAPS Rating: ****
GSK $52.18 Down -0.04 -0.07%
GlaxoSmithKline CAPS Rating: ****
NVO $171.93 Down -0.06 -0.03%
Novo Nordisk CAPS Rating: ****
AZN $51.61 Up +0.05 +0.10%
AstraZeneca plc (A… CAPS Rating: ****
BMY $43.92 Up +0.62 +1.43%
Bristol-Myers Squi… CAPS Rating: ****

Advertisement